Clayton Utz is acting for Tattarang, one of Australia’s largest private investment groups, on its investment in ASX-listed, Emyria Limited (ASX: EMD). The transaction was announced to the market today.
Perth-based Corporate partner Mark Paganin and special counsel Stephen Neale are leading our team working alongside Tattarang’s team, with support from lawyer Hannah Kim.
Tattarang’s $5 million investment into Emyria will take the form of a share placement, under which Tattarang will be issued 20 million shares at an issue price of $0.25 per share and 10 million options. Following completion of the placement, Tattarang will hold approximately 7.3% of Emyria.
Emyria is focused on accelerating treatment development and improving patient care. Its treatments target unmet needs and are focused on obtaining approval from major global regulators.
